Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging
with Hyperpolarized Pyruvate (HP) (13C) as a predictive response biomarker to androgen
signaling inhibition in patients with castration-resistant prostate cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Rahul Aggarwal University of California, San Francisco
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)